Global Melanoma Drug Market 2018-2024
11-May-2018 | Number of pages: 186 | Report Id: BMRC PH 115 | Report Format: | Status: Published

Brandessence Market Research is working on a new report title“Global Melanoma Drug Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024″. Increasing incidence of chronic diseases such as, skin cancer & skin allergies, aging population and changes in lifestyle are important driver of the market are key drivers for global Melanoma Drug market.

Global Melanoma Drug Market: Global Size, Trends, Competitive, Historical & Forecast Analysis, 2018-2024

Scope of Global Melanoma Drug Market Reports –

Melanoma is also known as malignant melanoma. It is a serious type of cancer that develops in melanocytes, the pigment cells present in the skin, it is more likely to grow and spread. The majority of skin cancers are caused by tanning beds which emits UV rays to speed up the skin tanning process and high exposure to the sun’s ultraviolet (UV) rays. UV-A and UV-B rays are the two types of UV rays that cause melanoma. Melanoma is divided into three categories: cutaneous, mucosal, and ocular. Cutaneous affects the skin, mucosal affects the mucous membrane in the mouth and nasal passage, and ocular affects the eye.

Drugs such as seviprotimut-L by Polynoma’s, Talimogene Laherparepvec (T-VEC) use together for the treatment of cutaneous melanoma are under development. Selumetinib is under development for the treatment of ocular melanoma. In 2011, Yervoy, a monoclonal antibody drug was developed for the treatment of melanoma and it is the first drug to receive FDA approval. Immunotherapy drugs include Opdivo (Nivolumab) and Keytruda (Pembrolizumab), which got FDA approval and created new opportunities in Melanoma treatment market.

BRAF inhibitor, was approved which accelerates tumor cell development and this change can boost the growth and spread of cancer cells. Therefore, these BRAF (B-Raf) drugs target the cancer-causing mutation. The BRAF oral medication should not be given to those without the mutation, as it could actually accelerate tumor progression. Testing for BRAF should be current with the COBAS (Agglomeration Community of the South Basin of Arcachon) test or other FDA approved tests. Side effects differ with fevers, rash, joint pain and nausea.

Global Melanoma Drug Market report is segmented on the basis of type, end user and Geography. Based on type Global Melanoma Drug Market is classified into Immunotherapy, Chemotherapy, Targeted Therapy, Biologic Therapy, Radiation Therapy, surgery and others. On the basis of end User Global Melanoma Drug Market is classified into Hospitals, Research Institute, Surgery Centers, Laboratories, Clinics and others.

The regions covered in Global Melanoma Drug Market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, Global Melanoma Drug Market sub divided in to U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

Key Players for Global Melanoma Drug Market Reports –

Global Melanoma Drug Market reports cover prominent players like Amgen, Inc., Bristol-Myers Squibb, Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Genentech Inc. Janssen Biotech, Inc., Novartis International AG, Pfizer, Vical, Ziopharm, Sanofi, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals, Enzon Pharmaceuticals, GlaxoSmithKline, Merck, Navidea Biopharmaceuticals, One Pharmaceuticals, Bayer, Celgene Corporation, AB Science, Array Biopharma ,AVAX Technologies, BioVex, Medarex, OnlyX Pharmaceuticals, Sun Pharmaceuticals, Plexxicon, QIAGEN, Reliance Life Sciences, Servier, TC Biopharm, Viragen and AstraZeneca.

Global Melanoma Drug Market Dynamics –

Global melanoma drugs market is mainly driven by growing incidences of target diseases such as Meningitis, Neonatal Tetanus, Diphtheria and Pertussis across the world. The development of novel drugs and combination therapy with minor side effects and enhanced survival are other key drivers for Global Melanoma Drug Market. Nonetheless, the high price of combination therapies i.e. USD 1,26,000 – USD 2,56,000 and clinical trials i.e. USD 7000 – USD 10000 coupled along with possible adverse events or side effects like nausea, vomiting, tiredness, constipation, Fever, Loss of Appetite and lowered blood count are the major restraints that may limit the growth of the market.

The number of people affected due to myeloma is 6.7 per 100,000 men and women per year. The number of deaths was 3.3 per 100,000 men and women per year. These rates are age-adjusted and based on 2011-2015 cases and deaths. During 2013-2015, approximately 0.8 percent of men and women will be diagnosed with myeloma. In 2018, it is expected that there will be 91,270 new cases of melanoma in the United States and 9,320 deaths from the disease 55,150 cases of invasive melanoma will occur in males and 36,120 cases of invasive melanoma will occur in females.

The opportunities for global Melanoma Drug market includes upcoming advance technologies Nonetheless development in personalized medicine along with huge investment in anti-melanoma drugs research will boost the global Melanoma Drug market. Also development of novel drugs and combination therapy with less side effects and better survival rates is expected to increase the global melanoma drug market. However, lack of novel and successful therapies in the market to reduce the risk of mortality of advanced metastatic melanoma patients are restraints for this market. High price of combination therapies such as USD 215 million and clinical trial with side effects will decrease the melanoma drug market.

Global Melanoma Drug Market Regional Analysis –

North America held a dominant share of the Global Melanoma Drug due to growing incidence of melanoma and other skin cancers. The U.S. government has developed favorable reimbursement policies for treatment of these diseases to fulfill unmet patient needs. This is likely to provide a healthy platform for growth to the North American market. Furthermore, owing to patent expiration of biologics in near future, various new players are expected to come into the market. The existing players are undertaking various strategic initiatives to raise their revenue share The Asia Pacific market is estimated to mature at a profitable rate owing to steady increase in the incidence of skin cancer coupled with increased demand for cost-effective therapeutics. Due to presence of large number of clinical research organizations, several pharmaceutical companies are drawn to this region for production of effective and cheaper drugs. Furthermore, increase in awareness of disease and government initiatives for improving health care facilities are expected to boost the regional market to a certain extent.

Key Benefits for Global Melanoma Drug Market Reports –

  • Global Melanoma Drug market report covers in depth historical and forecast analysis.
  • Global Melanoma Drug market research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Global market sale (K Units), Global market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
  • Global Melanoma Drug market report helps to identify opportunities in market place.
  • Global Melanoma Drug market report covers extensive analysis of emerging trends and competitive landscape.

Global Melanoma Drug Market Segmentation –

 Global Melanoma Drug Market: By Type Analysis

  • Immunotherapy
  • Chemotherapy
  • Targeted Therapy
  • Biologic Therapy
  • Radiation Therapy
  • surgery
  • others

Global Melanoma Drug Market: By End User Analysis

  • Hospitals
  • Research Institute
  • Surgery Centers
  • Laboratories
  • Clinics
  • Others

Global Melanoma Drug Market: by Regional & Country Analysis

  • North America
    • U.S.
    • Mexico
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
  • Asia Pacific
    • China
    • Japan
    • India
    • Southeast Asia
  • Latin America
    • Brazil
  • The Middle East and Africa
    • GCC
    • Africa
    • Rest of Middle East and Africa

Global Melanoma Drug Market 2018-2024

Our 186 pages report provides 57 tables, 73 charts and graphs. The report covers historical and forecast data of North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Our study focuses on the most lucrative areas in the industry and the future market prospects. Market covers financial results, trends, opportunities and revenue predictions from 2018 to 2024. Significant rise in research and development activities by leading vendors.

Why you should buy this report:

  • To receive a comprehensive analysis of the prospects for Global Melanoma Drug Market

To receive forecasts of Global Melanoma Drug Market

Sales in leading country markets from 2018-2024, including leading and emerging country from developed and developing regions 

  • To discover the views of experts in the Global Melanoma Drug Market sector
  • To determine the forces and factor that influences the market for Global Melanoma Drug Market: drivers, restraints, opportunities and threats
  • To find out where the Global Melanoma Drug Market is heading – both technologically and commercially from 2018-2024
  • Report Include tables of contract/projects and its value and description by region and Country

Global Melanoma Drug Market: By Region

 2017

(USD Million)

2024

(USD Million)

2017 Market Share (%)CAGR (%)

2018-2024

Consumption

(K Unit)

GlobalXXXXXXXXXX
North AmericaXXXXXXXXXX
EuropeXXXXXXXXXX
Asia PacificXXXXXXXXXX
Latin AmericaXXXXXXXXXX
Middle East & AfricaXXXXXXXXXX
GlobalXXXXXXXXXX

Source: Brandessence Market Research, 2018

Global Melanoma Drug Market: By Product Type

 2017

(USD Million)

2024

(USD Million)

2017 Market Share (%)CAGR (%)

2018-2024

Consumption

(K Unit)

ImmunotherapyXXXXXXXXXX
ChemotherapyXXXXXXXXXX
Targeted TherapyXXXXXXXXXX
Biologic TherapyXXXXXXXXXX
Radiation TherapyXXXXXXXXXX
Surgery
OthersXXXXXXXXXX

Source: Brandessence Market Research, 2018

Global Melanoma Drug Market: By End User

2017

(USD Million)

2024

(USD Million)

2017 Market Share (%)CAGR (%)

2018-2024

Consumption

(K Unit)

HospitalsXXXXXXXXXX
Research InstituteXXXXXXXXXX
Surgery Centres XXXXXXXXXX
LaboratoriesXXXXXXXXXX
ClinicsXXXXXXXXXX
OthersXXXXXXXXXX

Source: Brandessence Market Research, 2018

Why You Must Buy This Report:

  • This report features news, insights, the latest developments and an in depth survey of Global Melanoma Drug Market with up-to-date analysis as well as tables, graphs and charts. This report is a vital addition to gaining an understanding of this market sector and will give your company ‘the edge’ on your competitors.

Email me today to order this report or to ask for assistance. I look forward to receiving your email on sales@brandessenceresearch.com

Companies Mentioned in This Report,

  • Amgen,
  • Bristol-Myers Squibb Eisai Co. Ltd.
  • Hoffmann-La Roche Ltd.
  • Genentech Inc. Janssen Biotech, Inc.
  • Novartis International AG
  • Pfizer
  • Vical
  • Ziopharm
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceuticals
  • Enzon Pharmaceuticals
  • GlaxoSmithKline
  • Merck
  • Navidea Biopharmaceuticals
  • One Pharmaceuticals
  • Bayer
  • Celgene Corporation
  • AB Science
  • Array Biopharma
  • AVAX Technologies
  • BioVex
  • Medarex
  • OnlyX Pharmaceuticals
  • Sun Pharmaceuticals
  • Plexxicon
  • QIAGEN
  • Reliance Life Sciences
  • Servier
  • TC Biopharm
  • Viragen
  • AstraZeneca
  • Others